Skip to content
2000
image of Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone
file format pdf download PDF

Abstract

Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin–angiotensin–aldosterone system inhibitors and sodium–glucose cotransporter-2 inhibitors, are effective in slowing CKD progression. However, these approaches are insufficient to comprehensively inhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significant driver of inflammation, fibrosis, and oxidative stress. These pathological processes accelerate kidney damage and cardiovascular complications. Finerenone—a nonsteroidal mineralocorticoid receptor antagonist—represents a new frontier in renal protection. Unlike steroidal mineralocorticoid antagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammation and fibrosis without significantly raising serum potassium levels. Landmark trials have demonstrated the ability of finerenone to significantly reduce kidney and cardiovascular events in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effective option for slowing DKD progression while maintaining a favorable safety profile. Based on these findings, recent guidelines have incorporated finerenone as a recommended therapy for patients with T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks. This review provides a comprehensive overview of the available data to offer a deeper understanding of the potential of finerenone to transform CKD management for T2D patients.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303350851241021105850
2025-01-08
2025-11-01

  • From This Site

    /content/journals/emiddt/10.2174/0118715303350851241021105850
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/10.2174/0118715303350851241021105850/BMS-EMIDDT-2024-332.html?itemId=/content/journals/emiddt/10.2174/0118715303350851241021105850&mimeType=html&fmt=ahah

References

  1. Gross J.L. de Azevedo M.J. Silveiro S.P. Canani L.H. Caramori M.L. Zelmanovitz T. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005 28 1 164 176 10.2337/diacare.28.1.164 15616252
    [Google Scholar]
  2. Dekkers C.C.J. Gansevoort R.T. Heerspink H.J.L. New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors. Curr. Diab. Rep. 2018 18 5 27 10.1007/s11892‑018‑0992‑6 29589183
    [Google Scholar]
  3. van Baar M.J.B. van der Aart A.B. Hoogenberg K. Joles J.A. Heerspink H.J.L. van Raalte D.H. The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. Ther. Adv. Endocrinol. Metab. 2019 10 2042018819865398 10.1177/2042018819865398 31384419
    [Google Scholar]
  4. Dasgupta I. Banerjee D. Chowdhury T.A. De P. Wahba M. Bain S. Frankel A. Fogarty D. Pokrajac A. Winocour P.H. Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease. Br. J. Diabetes 2017 17 4 160 164 10.15277/bjd.2017.152
    [Google Scholar]
  5. Rich S.S. Genetic contribution to risk for diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2018 13 8 1135 1137 10.2215/CJN.07240618 30012628
    [Google Scholar]
  6. Bansal N. Katz R. Robinson-Cohen C. Odden M.C. Dalrymple L. Shlipak M.G. Sarnak M.J. Siscovick D.S. Zelnick L. Psaty B.M. Kestenbaum B. Correa A. Afkarian M. Young B. de Boer I.H. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease. JAMA Cardiol. 2017 2 3 314 318 10.1001/jamacardio.2016.4652 28002548
    [Google Scholar]
  7. Afkarian M. Sachs M.C. Kestenbaum B. Hirsch I.B. Tuttle K.R. Himmelfarb J. de Boer I.H. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013 24 2 302 308 10.1681/ASN.2012070718 23362314
    [Google Scholar]
  8. Kitamura H. Tanaka S. Hiyamuta H. Shimamoto S. Tsuruya K. Nakano T. Kitazono T. Cardiovascular risk factor burden and treatment control in patients with chronic kidney disease: A cross-sectional study. J. Atheroscler. Thromb. 2023 30 9 1210 1288 10.5551/jat.63891 36596531
    [Google Scholar]
  9. Foster M.C. Rawlings A.M. Marrett E. Neff D. Willis K. Inker L.A. Coresh J. Selvin E. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am. Heart J. 2013 166 1 150 156.e1 10.1016/j.ahj.2013.03.016 23816034
    [Google Scholar]
  10. Leon B.M. Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes 2015 6 13 1246 1258 10.4239/wjd.v6.i13.1246 26468341
    [Google Scholar]
  11. Dal Canto E. Ceriello A. Rydén L. Ferrini M. Hansen T.B. Schnell O. Standl E. Beulens J.W.J. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol. 2019 26 2_suppl Suppl. 25 32 10.1177/2047487319878371 31722562
    [Google Scholar]
  12. Heerspink H.J.L. Karasik A. Thuresson M. Melzer-Cohen C. Chodick G. Khunti K. Wilding J.P.H. Garcia Rodriguez L.A. Cea-Soriano L. Kohsaka S. Nicolucci A. Lucisano G. Lin F.J. Wang C.Y. Wittbrodt E. Fenici P. Kosiborod M. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020 8 1 27 35 10.1016/S2213‑8587(19)30384‑5 31862149
    [Google Scholar]
  13. Giugliano D. Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc. Diabetol. 2019 18 1 94 10.1186/s12933‑019‑0899‑9 31337395
    [Google Scholar]
  14. Perkovic V. Jardine M.J. Neal B. Bompoint S. Heerspink H.J.L. Charytan D.M. Edwards R. Agarwal R. Bakris G. Bull S. Cannon C.P. Capuano G. Chu P.L. de Zeeuw D. Greene T. Levin A. Pollock C. Wheeler D.C. Yavin Y. Zhang H. Zinman B. Meininger G. Brenner B.M. Mahaffey K.W. CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260
    [Google Scholar]
  15. Agarwal R. Joseph A. Anker S.D. Filippatos G. Rossing P. Ruilope L.M. Pitt B. Kolkhof P. Scott C. Lawatscheck R. Wilson D.J. Bakris G.L. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J. Am. Soc. Nephrol. 2022 33 1 225 237 10.1681/ASN.2021070942 34732509
    [Google Scholar]
  16. Bakris G.L. Agarwal R. Chan J.C. Cooper M.E. Gansevoort R.T. Haller H. Remuzzi G. Rossing P. Schmieder R.E. Nowack C. Kolkhof P. Joseph A. Pieper A. Kimmeskamp-Kirschbaum N. Ruilope L.M. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. JAMA 2015 314 9 884 894 10.1001/jama.2015.10081 26325557
    [Google Scholar]
  17. Bakris G.L. Agarwal R. Anker S.D. Pitt B. Ruilope L.M. Rossing P. Kolkhof P. Nowack C. Schloemer P. Joseph A. Filippatos G. FIDELIO-DKD Investigators Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020 383 23 2219 2229 10.1056/NEJMoa2025845 33264825
    [Google Scholar]
  18. Bauersachs J. Jaisser F. Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015 65 2 257 263 10.1161/HYPERTENSIONAHA.114.04488 25368026
    [Google Scholar]
  19. Panizo S. Martínez-Arias L. Alonso-Montes C. Cannata P. Martín-Carro B. Fernández-Martín J.L. Naves-Díaz M. Carrillo-López N. Cannata-Andía J.B. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int. J. Mol. Sci. 2021 22 1 408 10.3390/ijms22010408 33401711
    [Google Scholar]
  20. Chaudhuri A. Ghanim H. Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes. Metab. 2022 24 3 365 376 10.1111/dom.14601 34779091
    [Google Scholar]
  21. Tesch G.H. Young M.J. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front. Pharmacol. 2017 8 313 10.3389/fphar.2017.00313 28611666
    [Google Scholar]
  22. Solis-Herrera C. Triplitt C. Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Diabetes Obes. Metab. 2024 26 2 417 430 10.1111/dom.15327 37885354
    [Google Scholar]
  23. Buonafine M. Bonnard B. Jaisser F. Mineralocorticoid receptor and cardiovascular disease. Am. J. Hypertens. 2018 31 11 1165 1174 10.1093/ajh/hpy120 30192914
    [Google Scholar]
  24. Gomez-Sanchez E. Gomez-Sanchez C.E. The multifaceted mineralocorticoid receptor. Compr. Physiol. 2014 4 3 965 994 10.1002/cphy.c130044 24944027
    [Google Scholar]
  25. Agarwal R. Kolkhof P. Bakris G. Bauersachs J. Haller H. Wada T. Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 2021 42 2 152 161 10.1093/eurheartj/ehaa736 33099609
    [Google Scholar]
  26. Pitt B. Zannad F. Remme W.J. Cody R. Castaigne A. Perez A. Palensky J. Wittes J. Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999 341 10 709 717 10.1056/NEJM199909023411001 10471456
    [Google Scholar]
  27. Morales J. Palmer B.F. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review. Postgrad. Med. 2024 136 2 111 119 10.1080/00325481.2024.2316572 38344772
    [Google Scholar]
  28. Pitt B. Pfeffer M.A. Assmann S.F. Boineau R. Anand I.S. Claggett B. Clausell N. Desai A.S. Diaz R. Fleg J.L. Gordeev I. Harty B. Heitner J.F. Kenwood C.T. Lewis E.F. O’Meara E. Probstfield J.L. Shaburishvili T. Shah S.J. Solomon S.D. Sweitzer N.K. Yang S. McKinlay S.M. TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014 370 15 1383 1392 10.1056/NEJMoa1313731 24716680
    [Google Scholar]
  29. KDIGO Executive Committee. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney disease. 2024
    [Google Scholar]
  30. de Boer I.H. Khunti K. Sadusky T. Tuttle K.R. Neumiller J.J. Rhee C.M. Rosas S.E. Rossing P. Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022 45 12 3075 3090 10.2337/dci22‑0027 36189689
    [Google Scholar]
  31. ElSayed N.A. Aleppo G. Aroda V.R. Bannuru R.R. Brown F.M. Bruemmer D. Collins B.S. Das S.R. Hilliard M.E. Isaacs D. Johnson E.L. Kahan S. Khunti K. Kosiborod M. Leon J. Lyons S.K. Perry M.L. Prahalad P. Pratley R.E. Seley J.J. Stanton R.C. Gabbay R.A. on behalf of the American Diabetes Association Cardiovascular disease and risk management: Standards of care in diabetes. Diabetes Care 2023 46 Suppl. 1 S158 S190 10.2337/dc23‑S010 36507632
    [Google Scholar]
  32. Shaikh A. Ray J. Campbell K.N. Role of finerenone in the treatment of diabetic kidney disease: Patient selection and clinical perspectives. Ther. Clin. Risk Manag. 2022 18 753 760 10.2147/TCRM.S325916 35937973
    [Google Scholar]
  33. Jaisser F. Farman N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol. Rev. 2016 68 1 49 75 10.1124/pr.115.011106 26668301
    [Google Scholar]
  34. Verma A. Vaidya A. Subudhi S. Waikar S.S. Aldosterone in chronic kidney disease and renal outcomes. Eur. Heart J. 2022 43 38 3781 3791 10.1093/eurheartj/ehac352 36219773
    [Google Scholar]
  35. Palanisamy S. Funes Hernandez M. Chang T.I. Mahaffey K.W. Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist. Cardiol. Ther. 2022 11 3 337 354 10.1007/s40119‑022‑00269‑3 35737275
    [Google Scholar]
  36. Bakris G.L. Jaisser F. Aldosterone excess and cardiorenal risk: More common than appreciated. Eur. Heart J. 2022 43 38 3792 3793 10.1093/eurheartj/ehac410 36219774
    [Google Scholar]
  37. Lother A. Mineralocorticoid Receptors. Circ. Res. 2020 127 3 354 356 10.1161/CIRCRESAHA.120.317424 32673533
    [Google Scholar]
  38. Belden Z. Deiuliis J.A. Dobre M. Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature. Am. J. Nephrol. 2017 46 4 298 314 10.1159/000480652 29017166
    [Google Scholar]
  39. Barrera-Chimal J. Girerd S. Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis. Kidney Int. 2019 96 2 302 319 10.1016/j.kint.2019.02.030 31133455
    [Google Scholar]
  40. Liu W. Yu S. Nonsteroidal mineralocorticoid receptor antagonist eliciting cardiorenal protection is a new option for patients with chronic kidney disease. Kidney Dis. 2023 9 1 12 25 10.1159/000528066 36756081
    [Google Scholar]
  41. Kintscher U. Bakris G.L. Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br. J. Pharmacol. 2022 179 13 3220 3234 10.1111/bph.15747 34811750
    [Google Scholar]
  42. Lerma E. White W.B. Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad. Med. 2023 135 3 224 233 10.1080/00325481.2022.2060598 35392754
    [Google Scholar]
  43. Lavall D. Jacobs N. Mahfoud F. Kolkhof P. Böhm M. Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem. Pharmacol. 2019 168 173 183 10.1016/j.bcp.2019.07.001 31283930
    [Google Scholar]
  44. Lv R. Xu L. Che L. Liu S. Wang Y. Dong B. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front. Endocrinol. (Lausanne) 2023 14 1125693 10.3389/fendo.2023.1125693 36860374
    [Google Scholar]
  45. González-Juanatey J.R. Górriz J.L. Ortiz A. Valle A. Soler M.J. Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann. Med. 2023 55 1 502 513 10.1080/07853890.2023.2171110 36719097
    [Google Scholar]
  46. Massy Z.A. Drueke T.B. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int. Rep. 2024 9 9 2608 2618 10.1016/j.ekir.2024.05.033 39291205
    [Google Scholar]
  47. Pitt B. Filippatos G. Agarwal R. Anker S.D. Bakris G.L. Rossing P. Joseph A. Kolkhof P. Nowack C. Schloemer P. Ruilope L.M. FIGARO-DKD Investigators Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 2021 385 24 2252 2263 10.1056/NEJMoa2110956 34449181
    [Google Scholar]
  48. Ruilope L.M. Pitt B. Anker S.D. Rossing P. Kovesdy C.P. Pecoits-Filho R. Pergola P. Joseph A. Lage A. Mentenich N. Scheerer M.F. Bakris G.L. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol. Dial. Transplant. 2023 38 2 372 383 10.1093/ndt/gfac157 35451488
    [Google Scholar]
  49. Agarwal R. Filippatos G. Pitt B. Anker S.D. Rossing P. Joseph A. Kolkhof P. Nowack C. Gebel M. Ruilope L.M. Bakris G.L. FIDELIO-DKD and FIGARO-DKD investigators Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 2022 43 6 474 484 10.1093/eurheartj/ehab777 35023547
    [Google Scholar]
  50. Pitt B. Kober L. Ponikowski P. Gheorghiade M. Filippatos G. Krum H. Nowack C. Kolkhof P. Kim S.Y. Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 2013 34 31 2453 2463 10.1093/eurheartj/eht187 23713082
    [Google Scholar]
  51. Filippatos G. Anker S.D. Böhm M. Gheorghiade M. Køber L. Krum H. Maggioni A.P. Ponikowski P. Voors A.A. Zannad F. Kim S.Y. Nowack C. Palombo G. Kolkhof P. Kimmeskamp-Kirschbaum N. Pieper A. Pitt B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 2016 37 27 2105 2114 10.1093/eurheartj/ehw132 27130705
    [Google Scholar]
  52. Zheng Y. Ma S. Huang Q. Fang Y. Tan H. Chen Y. Li C. Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease. Kidney Blood Press. Res. 2022 47 4 219 228 10.1159/000521908 35034019
    [Google Scholar]
  53. Kolkhof P. Delbeck M. Kretschmer A. Steinke W. Hartmann E. Bärfacker L. Eitner F. Albrecht-Küpper B. Schäfer S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 2014 64 1 69 78 10.1097/FJC.0000000000000091 24621652
    [Google Scholar]
  54. Amazit L. Le Billan F. Kolkhof P. Lamribet K. Viengchareun S. Fay M.R. Khan J.A. Hillisch A. Lombès M. Rafestin-Oblin M.E. Fagart J. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J. Biol. Chem. 2015 290 36 21876 21889 10.1074/jbc.M115.657957 26203193
    [Google Scholar]
  55. Schwenk M.H. Hirsch J.S. Bomback A.S. Aldosterone blockade in CKD: Emphasis on pharmacology. Adv. Chronic Kidney Dis. 2015 22 2 123 132 10.1053/j.ackd.2014.08.003 25704349
    [Google Scholar]
  56. Gerisch M. Heinig R. Engelen A. Lang D. Kolkhof P. Radtke M. Platzek J. Lovis K. Rohde G. Schwarz T. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab. Dispos. 2018 46 11 1546 1555 10.1124/dmd.118.083337 30171161
    [Google Scholar]
  57. Heinig R. Kimmeskamp-Kirschbaum N. Halabi A. Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94–8862) in individuals with renal impairment. Clin. Pharmacol. Drug Dev. 2016 5 6 488 501 10.1002/cpdd.263 27431783
    [Google Scholar]
  58. Agarwal R. Rossignol P. Romero A. Garza D. Mayo M.R. Warren S. Ma J. White W.B. Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019 394 10208 1540 1550 10.1016/S0140‑6736(19)32135‑X 31533906
    [Google Scholar]
  59. Grune J. Beyhoff N. Smeir E. Chudek R. Blumrich A. Ban Z. Brix S. Betz I.R. Schupp M. Foryst-Ludwig A. Klopfleisch R. Stawowy P. Houtman R. Kolkhof P. Kintscher U. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity. Hypertension 2018 71 4 599 608 10.1161/HYPERTENSIONAHA.117.10360 29437893
    [Google Scholar]
  60. Barrera-Chimal J. Kolkhof P. Lima-Posada I. Alexandre J. Rossignol P. Jaisser F. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin. Investig. Drugs 2021 30 11 1141 1157 10.1080/13543784.2021.2002844 34758679
    [Google Scholar]
  61. Zhu S. Li J. Zhao X. Comparative risk of new-onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A bayesian network meta-analysis. Int. J. Clin. Pract. 2021 75 8 e13940 10.1111/ijcp.13940 33332696
    [Google Scholar]
  62. Agarwal R. Pitt B. Palmer B.F. Kovesdy C.P. Burgess E. Filippatos G. Małyszko J. Ruilope L.M. Rossignol P. Rossing P. Pecoits-Filho R. Anker S.D. Joseph A. Lawatscheck R. Wilson D. Gebel M. Bakris G.L. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin. Kidney J. 2023 16 2 293 302 10.1093/ckj/sfac234 36864892
    [Google Scholar]
  63. Pei H. Wang W. Zhao D. Wang L. Su G.H. Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure. Medicine (Baltimore) 2018 97 16 e0254 10.1097/MD.0000000000010254 29668577
    [Google Scholar]
  64. Pitt B. Pedro Ferreira J. Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur. Heart J. Cardiovasc. Pharmacother. 2017 3 1 48 57 10.1093/ehjcvp/pvw016 27530337
    [Google Scholar]
  65. Patoulias D. Katsimardou A. Sviggou A. Kordalis V. Aidinis A. Imprialos K. Stavropoulos K. Karagiannis A. Papadopoulos C. Doumas M. Major adverse events with the use of finerenone in patients with type 2 diabetes mellitus: a meta-analysis of cardiovascular outcome trials. J. Hypertens. 2022 40 Suppl. 1 e158 e159 10.1097/01.hjh.0000836960.12035.10
    [Google Scholar]
  66. Rieg T. Vallon V. Sausbier M. Sausbier U. Kaissling B. Ruth P. Osswald H. The role of the BK channel in potassium homeostasis and flow-induced renal potassium excretion. Kidney Int. 2007 72 5 566 573 10.1038/sj.ki.5002369 17579662
    [Google Scholar]
  67. Sarnowski A. Gama R.M. Dawson A. Mason H. Banerjee D. Hyperkalemia in chronic kidney disease: Links, risks and management. Int. J. Nephrol. Renovasc. Dis. 2022 15 215 228 10.2147/IJNRD.S326464 35942480
    [Google Scholar]
  68. Fountain JH Kaur J Lappin SL Physiology, Renin Angiotensin System. StatPearls 2023
    [Google Scholar]
  69. Palmer B.F. Clegg D.J. Physiology and pathophysiology of potassium homeostasis: Core curriculum 2019. Am. J. Kidney Dis. 2019 74 5 682 695 10.1053/j.ajkd.2019.03.427 31227226
    [Google Scholar]
  70. Vaidya A. Mulatero P. Baudrand R. Adler G.K. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 2018 39 6 1057 1088 10.1210/er.2018‑00139 30124805
    [Google Scholar]
  71. Hundemer G.L. Sood M.M. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol. Res. 2021 172 105835 10.1016/j.phrs.2021.105835 34438065
    [Google Scholar]
  72. Whitlock R. Leon S.J. Manacsa H. Askin N. Rigatto C. Fatoba S.T. Farag Y.M.K. Tangri N. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: A systematic review and meta-analysis. Nephrol. Dial. Transplant. 2023 38 11 2503 2516 10.1093/ndt/gfad101 37309038
    [Google Scholar]
  73. Palmer B.F. Clegg D.J. Extrarenal effects of aldosterone on potassium homeostasis. Kidney360 2022 3 3 561 568 10.34067/KID.0006762021 35582177
    [Google Scholar]
  74. Ashjian E. Clarke M. Pogue K. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am. J. Health Syst. Pharm. 2023 80 23 1708 1721 10.1093/ajhp/zxad192 37632460
    [Google Scholar]
  75. Jiang X. Zhang Z. Li C. Zhang S. Su Q. Yang S. Liu X. Hu Y. Pu X. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: A systematic review incorporating an indirect comparisons meta-analysis. Front. Pharmacol. 2022 13 896947 10.3389/fphar.2022.896947 35784710
    [Google Scholar]
  76. Goldman J.D. Optimizing finerenone in people with diabetes and chronic kidney disease: an opportunity for the pharmacist. J. Pharm. Pract. 2024 08971900241256725 10.1177/08971900241256725 38807033
    [Google Scholar]
  77. Dunn J.D. Benton W.W. Orozco-Torrentera E. Adamson R.T. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am. J. Manag. Care 2015 21 15 Suppl. s307 s315 26788745
    [Google Scholar]
  78. Rossignol P. Legrand M. Kosiborod M. Hollenberg S.M. Peacock W.F. Emmett M. Epstein M. Kovesdy C.P. Yilmaz M.B. Stough W.G. Gayat E. Pitt B. Zannad F. Mebazaa A. Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacol. Res. 2016 113 Pt A 585 591 10.1016/j.phrs.2016.09.039 27693804
    [Google Scholar]
  79. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 102 5S S1 S127 36272764
    [Google Scholar]
  80. American Diabetes Association Professional Practice Committee 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022 45 Suppl. 1 S125 S143 10.2337/dc22‑S009 34964831
    [Google Scholar]
  81. Mancia G. Kreutz R. Brunström M. Burnier M. Grassi G. Januszewicz A. Muiesan M.L. Tsioufis K. Agabiti-Rosei E. Algharably E.A.E. Azizi M. Benetos A. Borghi C. Hitij J.B. Cifkova R. Coca A. Cornelissen V. Cruickshank J.K. Cunha P.G. Danser A.H.J. Pinho R.M. Delles C. Dominiczak A.F. Dorobantu M. Doumas M. Fernández-Alfonso M.S. Halimi J.M. Járai Z. Jelaković B. Jordan J. Kuznetsova T. Laurent S. Lovic D. Lurbe E. Mahfoud F. Manolis A. Miglinas M. Narkiewicz K. Niiranen T. Palatini P. Parati G. Pathak A. Persu A. Polonia J. Redon J. Sarafidis P. Schmieder R. Spronck B. Stabouli S. Stergiou G. Taddei S. Thomopoulos C. Tomaszewski M. Van de Borne P. Wanner C. Weber T. Williams B. Zhang Z.Y. Kjeldsen S.E. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J. Hypertens. 2023 41 12 1874 2071 10.1097/HJH.0000000000003480 37345492
    [Google Scholar]
  82. Sarafidis P. Iatridi F. Ferro C. Alexandrou M.E. Fernandez-Fernandez B. Kanbay M. Mallamaci F. Nistor I. Rossignol P. Wanner C. Cozzolino M. Ortiz A. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin. Kidney J. 2023 16 11 1885 1907 10.1093/ckj/sfad139 37915899
    [Google Scholar]
  83. Marx N. Federici M. Schütt K. Müller-Wieland D. Ajjan R.A. Antunes M.J. Christodorescu R.M. Crawford C. Di Angelantonio E. Eliasson B. Espinola-Klein C. Fauchier L. Halle M. Herrington W.G. Kautzky-Willer A. Lambrinou E. Lesiak M. Lettino M. McGuire D.K. Mullens W. Rocca B. Sattar N. Prescott E. Cosentino F. Abdelhamid M. Aboyans V. Antoniou S. Asteggiano R. Baumgartner I. Buccheri S. Bueno H. Čelutkienė J. Chieffo A. Christersson C. Coats A. Cosyns B. Czerny M. Deaton C. Falk V. Ference B.A. Filippatos G. Fisher M. Huikuri H. Ibanez B. Jaarsma T. James S. Khunti K. Køber L. Koskinas K.C. Lewis B.S. Løchen M-L. McEvoy J.W. Mihaylova B. Mindham R. Neubeck L. Nielsen J.C. Parati G. Pasquet A.A. Patrono C. Petersen S.E. Piepoli M.F. Rakisheva A. Rossello X. Rossing P. Rydén L. Standl E. Tokgozoglu L. Touyz R.M. Visseren F. Volpe M. Vrints C. Witkowski A. Hazarapetyan L. Zirlik A. Rustamova Y. van de Borne P. Sokolović Š. Gotcheva N. Milicic D. Agathangelou P. Vrablík M. Schou M. Hasan-Ali H. Viigimaa M. Lautamäki R. Aboyans V. Klimiashvili Z. Kelm M. Siasos G. Kiss R.G. Libungan B. Durkan M. Zafrir B. Colivicchi F. Tundybayeva M. Bytyçi I. Mirrakhimov E. Trusinskis K. Saadé G. Badarienė J. Banu C-A. Magri C.J. Boskovic A. Hattaoui M.E. Martens F. Bosevski M. Knudsen E.C. Burchardt P. Fontes-Carvalho R. Vinereanu D. Mancini T. Beleslin B. Martinka E. Fras Z. Conde A.C. Mellbin L. Carballo D. Bsata W. Mghaieth F. Gungor B. Mitchenko O. Wheatcroft S. Trigulova R. Prescott E. James S. Arbelo E. Baigent C. Borger M.A. Buccheri S. Ibanez B. Køber L. Koskinas K.C. McEvoy J.W. Mihaylova B. Mindham R. Neubeck L. Nielsen J.C. Pasquet A.A. Rakisheva A. Rocca B. Rosselló X. Vaartjes I. Vrints C. Witkowski A. Zeppenfeld K. ESC Scientific Document Group 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 2023 44 39 4043 4140 10.1093/eurheartj/ehad192 37622663
    [Google Scholar]
  84. Ito S. Kashihara N. Shikata K. Nangaku M. Wada T. Okuda Y. Sawanobori T. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial. Clin. J. Am. Soc. Nephrol. 2020 15 12 1715 1727 10.2215/CJN.06870520 33239409
    [Google Scholar]
  85. Wada T. Inagaki M. Yoshinari T. Terata R. Totsuka N. Gotou M. Hashimoto G. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study. Clin. Exp. Nephrol. 2021 25 2 120 130 10.1007/s10157‑020‑01963‑z 32974732
    [Google Scholar]
  86. Bakris G. Pergola P.E. Delgado B. Genov D. Doliashvili T. Vo N. Yang Y.F. McCabe J. Benn V. Pitt B. BLOCK-CKD Study Group Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the block-ckd study. Hypertension 2021 78 1 74 81 10.1161/HYPERTENSIONAHA.121.17073 33966452
    [Google Scholar]
  87. Squire I.B. Gabrielsen A. Greasley P.J. Wernevik L. Hartleib-Geschwindner J. Holden J. Johansson S. Rudvik A. Sánchez J. Bamberg K. Melin J. Whittaker A. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. Clin. Transl. Sci. 2022 15 10 2493 2504 10.1111/cts.13377 35971596
    [Google Scholar]
  88. Marx N. Husain M. Lehrke M. Verma S. Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022 146 24 1882 1894 10.1161/CIRCULATIONAHA.122.059595 36508493
    [Google Scholar]
  89. Sattar N. Lee M.M.Y. Kristensen S.L. Branch K.R.H. Del Prato S. Khurmi N.S. Lam C.S.P. Lopes R.D. McMurray J.J.V. Pratley R.E. Rosenstock J. Gerstein H.C. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 9 10 653 662 10.1016/S2213‑8587(21)00203‑5 34425083
    [Google Scholar]
  90. Giugliano D. Longo M. Signoriello S. Maiorino M.I. Solerte B. Chiodini P. Esposito K. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc. Diabetol. 2022 21 1 42 10.1186/s12933‑022‑01474‑z 35296336
    [Google Scholar]
  91. Giugliano D. Maiorino M.I. Bellastella G. Esposito K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc. Diabetol. 2021 20 1 36 10.1186/s12933‑021‑01229‑2 33546683
    [Google Scholar]
  92. Di Lullo L Lavalle C Scatena A Mariani MV Ronco C Bellasi A Finerenone: Questions and answers—the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J. Clin. Med. 2023 12 12 3992
    [Google Scholar]
  93. Mårup F.H. Thomsen M.B. Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin. Kidney J. 2024 17 1 sfad249 10.1093/ckj/sfad249 38186886
    [Google Scholar]
  94. Provenzano M. Puchades M.J. Garofalo C. Jongs N. D’Marco L. Andreucci M. De Nicola L. Gorriz J.L. Heerspink H.J.L. ROTATE-3 study group ROTATE-3 study group members Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial. J. Am. Soc. Nephrol. 2022 33 8 1569 1580 10.1681/ASN.2022020207 35440501
    [Google Scholar]
  95. Heerspink H.J.L. Agarwal R. Bakris G.L. Cherney D.Z.I. Lam C.S.P. Neuen B.L. Sarafidis P.A. Tuttle K.R. Wanner C. Brinker M.D. Dizayee S. Kolkhof P. Schloemer P. Vesterinen P. Perkovic V. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol. Dial. Transplant. 2024 16 3 518 524 10.1093/ndt/gfae132 38858818
    [Google Scholar]
  96. Green J.B. Mottl A.K. Bakris G. Heerspink H.J.L. Mann J.F.E. McGill J.B. Nangaku M. Rossing P. Scott C. Gay A. Agarwal R. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transplant. 2023 38 4 894 903 10.1093/ndt/gfac198 35700142
    [Google Scholar]
  97. Desai N.R. Navaneethan S.D. Nicholas S.B. Pantalone K.M. Wanner C. Hamacher S. Gay A. Wheeler D.C. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. J. Diabetes Complications 2023 37 4 108411 10.1016/j.jdiacomp.2023.108411 36857997
    [Google Scholar]
  98. Heerspink H.J.L. Birkenfeld A.L. Cherney D.Z.I. Colhoun H.M. Ji L. Mathieu C. Groop P.H. Pratley R.E. Rosas S.E. Rossing P. Skyler J.S. Tuttle K.R. Lawatscheck R. Scott C. Edfors R. Scheerer M.F. Kolkhof P. McGill J.B. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res. Clin. Pract. 2023 204 110908 10.1016/j.diabres.2023.110908 37805000
    [Google Scholar]
  99. Schaefer F Montini G Kang HG Walle J Vande Zaritsky J Schreuder MF Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials 2024 25 1 203 10.1186/s13063‑024‑08021‑z
    [Google Scholar]
  100. The effect of finerenone in kidney transplantion recipients: The EFFEKTOR study. NCT06059664 2024
  101. Solomon S.D. Ostrominski J.W. Vaduganathan M. Claggett B. Jhund P.S. Desai A.S. Lam C.S.P. Pitt B. Senni M. Shah S.J. Voors A.A. Zannad F. Abidin I.Z. Alcocer-Gamba M.A. Atherton J.J. Bauersachs J. Ma C.S. Chiang C.E. Chioncel O. Chopra V. Comin-Colet J. Filippatos G. Fonseca C. Gajos G. Goland S. Goncalvesová E. Kang S.M. Katova T. Kosiborod M.N. Latkovskis G. Lee A.P.W. Linssen G.C.M. Llamas-Esperón G. Mareev V. Martinez F.A. Melenovský V. Merkely B. Nodari S. Petrie M.C. Saldarriaga C.I. Saraiva J.F.K. Sato N. Schou M. Sharma K. Troughton R. Udell J.A. Ukkonen H. Vardeny O. Verma S. von Lewinski D. Voronkov L.G. Yilmaz M.B. Zieroth S. Lay-Flurrie J. van Gameren I. Amarante F. Viswanathan P. McMurray J.J.V. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial. Eur. J. Heart Fail. 2024 26 6 1334 1346 10.1002/ejhf.3266 38733212
    [Google Scholar]
  102. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF). NCT06008197 2024
  103. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) (CONFIRMATION). NCT06024746 2024
  104. A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF). NCT06033950 2024
/content/journals/emiddt/10.2174/0118715303350851241021105850
Loading
Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone
Bentham Science Publishers ; https://doi.org/10.2174/0118715303350851241021105850
/content/journals/emiddt/10.2174/0118715303350851241021105850
/content/journals/emiddt/10.2174/0118715303350851241021105850
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Chronic kidney disease ; type 2 diabetes mellitus ; kidney replacement therapy ; finerenone ; diabetic kidney disease ; nonsteroidal mineralocorticoid receptor antagonists

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test